A few months after partnering a preclinical program with Serono SA, antibody development company Genmab A/S entered a potential $215 million deal with the Swiss biotech firm involving its Phase III candidate to treat cutaneous T-cell lymphoma. (BioWorld Today)
A few months after partnering a preclinical program with Serono SA, antibody development company Genmab A/S entered a potential $215 million deal with the Swiss biotech firm involving its Phase III candidate to treat cutaneous T-cell lymphoma. (BioWorld Today)
Just days after Alexion Pharmaceuticals Inc. said it completed enrollment in a pivotal trial of its cardiovascular drug, pexelizumab, ahead of schedule, the company priced a public offering to raise $66.9 million. (BioWorld Today)
Just days after Alexion Pharmaceuticals Inc. said it completed enrollment in a pivotal trial of its cardiovascular drug, pexelizumab, ahead of schedule, the company priced a public offering to raise $66.9 million. (BioWorld Today)
